Q-omics provides the consensus-scored SPTAN1 profile across patient tissues and cancer cell-line models. SPTAN1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SPTAN1 is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, SPTAN1 protein abundance shows 29,767 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, LIHC, and GBM as cancer lineages where SPTAN1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPTAN1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPTAN1 survival associations across molecular data types. SPTAN1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (11) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPTAN1 RNA expression–survival associations across cancer types. High SPTAN1 expression shows unfavorable associations in ACC, CESC, BLCA and MESO, but favorable associations in KIRC and SCLC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SPTAN1 RNA expression.
This table summarizes SPTAN1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 7. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SPTAN1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPTAN1 shows lower tumor expression in LUAD, UCEC and LUSC and higher tumor expression in LIHC, HNSC and STAD. The LIHC box plot shows higher SPTAN1 RNA expression in tumor versus normal tissue (log2 FC = +1.654, t-test p < 0.001).
This table shows molecular features associated with SPTAN1 in patient tissues and cancer cell lines. In patient samples, SPTAN1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SPTAN1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
